keyword
MENU ▼
Read by QxMD icon Read
search

Hypoactive sexual desire disorder

keyword
https://www.readbyqxmd.com/read/28291031/a-sex-specific-dose-response-curve-for-testosterone-could-excessive-testosterone-limit-sexual-interaction-in-women
#1
Jill M Krapf, James A Simon
Testosterone treatment increases sexual desire and well-being in women with hypoactive sexual desire disorder; however, many studies have shown only modest benefits limited to moderate doses. Unlike men, available data indicate women show a bell-shaped dose-response curve for testosterone, wherein a threshold dosage of testosterone leads to desirable sexual function effects, but exceeding this threshold results in a lack of further positive sexual effects or may have a negative impact. Emotional and physical side-effects of excess testosterone, including aggression and virilization, may counteract the modest benefits on sexual interaction, providing a possible explanation for a threshold dose of testosterone in women...
March 13, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28278441/facilitation-of-sexual-behavior-in-ovariectomized-rats-by-estradiol-and-testosterone-a-preclinical-model-of-androgen-effects-on-female-sexual-desire
#2
Sherri Lee Jones, Nafissa Ismail, James G Pfaus
In the United States and Canada, there are no approved treatments for hypoactive sexual desire disorder in postmenopausal women. Testosterone improves female sexual desire in naturally- and surgically-menopausal women maintained on estrogen replacement therapy, and long-term safety data from randomized placebo-controlled clinical trials has yielded promising results. However, the mechanisms associated with its efficacy are not known, and could be addressed using preclinical rodent models; yet there is no systematic evaluation of the effects of estradiol and testosterone on female rat sexual behavior...
February 17, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28203348/flibanserin-for-hypoactive-sexual-desire-disorder-place-in-therapy
#3
REVIEW
Faina Gelman, Jessica Atrio
The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access...
January 2017: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/28130017/what-women-want-an-explorative-study-on-women-s-attitudes-toward-sexuality-boosting-medication-in-a-sample-of-swiss-women
#4
Melanie Gutsche, Andrea Burri
INTRODUCTION: The recent approval of flibanserin to treat hypoactive sexual desire disorder in premenopausal women has once again fueled the ongoing debate about medicalization of female sexual problems and the necessity of such a drug. AIM: To investigate women's attitudes toward sexuality-boosting medication (SBM) and the role of factors potentially associated with these attitudes, including sexual functioning, sexual quality of life, relationship satisfaction, and personality, in an exploratory survey...
January 24, 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28117267/androgens-and-psychosocial-factors-related-to-sexual-dysfunctions-in-premenopausal-women
#5
Sarah Wåhlin-Jacobsen, Ellids Kristensen, Anette Tønnes Pedersen, Nanna Cassandra Laessøe, Arieh S Cohen, David M Hougaard, Marika Lundqvist, Annamaria Giraldi
INTRODUCTION: The female sexual response is complex and influenced by several biological, psychological, and social factors. Testosterone is believed to modulate a woman's sexual response and desire, because low levels are considered a risk factor for impaired sexual function, but previous studies have been inconclusive. AIM: To investigate how androgen levels and psychosocial factors are associated with female sexual dysfunction (FSD), including hypoactive sexual desire disorder (HSDD)...
January 20, 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28079402/sexual-dysfunction-in-premenopausal-women-could-be-related-to-hormonal-profile
#6
Fabiene Bernardes Castro Vale, Bruna Barbosa Coimbra, Gerson Pereira Lopes, Selmo Geber
Female sexual dysfunction (FSD) is a public health problem that affects women's quality of life. Although the relationship between some hormones and the FSD has been described, it is not well established for all hormones. Therefore, the aim of our study was to evaluate the association between hormonal dysfunction and sexual dysfunction in premenopausal women. We performed a cross-sectional study with 60 patients with regular menstrual cycles, with age ranging from 18 to 44 years, with previous diagnosis of FSD...
February 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28050188/psychometric-properties-of-the-sexual-interest-and-desire-inventory-female-for-diagnosis-of-hypoactive-sexual-desire-disorder-the-persian-version
#7
Mina Malary, Mehdi Pourasghar, Soghra Khani, Mahmood Moosazadeh, Zeinab Hamzehgardeshi
Objective: Hypoactive sexual desire Disorder (HSDD) is a common sexual problem among women. Sexual interest and desire inventory -female (SIDI-F) has been widely validated and used to measure sexual desire in women. The aim of this study was to determine the psychometric properties of the Persian version of SIDI-F for Iranian population. Method: This was a methodological study on the psychometric properties of SIDI -F. This report describes the process and principles used in the translation and cultural adaptation of the SIDI-F on 40 women of reproductive age who were selected using convenience sampling method...
October 2016: Iranian Journal of Psychiatry
https://www.readbyqxmd.com/read/28041924/what-sexual-behaviors-relate-to-decreased-sexual-desire-in-women-a-review-and-proposal-for-end-points-in-treatment-trials-for-hypoactive-sexual-desire-disorder
#8
REVIEW
Robert Pyke, Anita Clayton
INTRODUCTION: Counts of satisfying sexual events (SSEs) per month have been criticized as an end point in treatment trials of women with hypoactive sexual desire disorder (HSDD) but grounding improvement in sexual desire by assessing changes in sexual behavior remains of some importance. METHODS: We conducted a literature review to find validated measurements that are specific sexual behavioral correlates of low sexual desire. We compared expert-proposed criteria for dysfunctional desire, expert-developed sets of scale items, and self-rated scales developed before issuance of, or in accordance with, the Food and Drug Administration's guidance on developing patient-reported outcomes...
December 29, 2016: Sexual Medicine
https://www.readbyqxmd.com/read/27916394/hypoactive-sexual-desire-disorder-international-society-for-the-study-of-women-s-sexual-health-isswsh-expert-consensus-panel-review
#9
REVIEW
Irwin Goldstein, Noel N Kim, Anita H Clayton, Leonard R DeRogatis, Annamaria Giraldi, Sharon J Parish, James Pfaus, James A Simon, Sheryl A Kingsberg, Cindy Meston, Stephen M Stahl, Kim Wallen, Roisin Worsley
The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels...
January 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/27916205/efficacy-and-safety-of-transdermal-testosterone-in-postmenopausal-women-with-hypoactive-sexual-desire-disorder-a-systematic-review-and-meta-analysis
#10
Chiara Achilli, Jyotsna Pundir, Parimalam Ramanathan, Luca Sabatini, Haitham Hamoda, Nick Panay
OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD). DESIGN: Systematic reviews and meta-analysis. SETTING: Not applicable. PATIENT(S): Seven randomized controlled trials enrolled 3,035 participants; 1,350 women were randomized to treatment with T patch, and 1,379 women were randomized to placebo...
February 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/27875946/the-role-of-sexual-dysfunction-and-infertility-on-reproductive-health-in-diabetics-pathogenesis-evaluation-and-management
#11
Jason Gandhi, Gautam Dagur, Kelly Warren, Noel Smith, Sardar Ali Khan
BACKGROUND: Uncontrolled or long-term diabetes mellitus is conducive to vascular and oxidative stress disturbances that impede several physiological systems, which may in turn elicit psychological symptoms. OBJECTIVE: We assess the sexual and hormonal complications of diabetes mellitus that impair reproductive function in males and females. METHOD: A comprehensive MEDLINE® search was guided using key words relevant to diabetes mellitus and reproductive health...
November 22, 2016: Current Diabetes Reviews
https://www.readbyqxmd.com/read/27872027/how-the-emotional-motor-system-controls-the-pelvic-organs
#12
REVIEW
Gert Holstege
INTRODUCTION: The brain has two goals: survival of the individual and survival of the species. It ensures that the body resides in safe circumstances and can obtain sufficient drink and food. It also has to produce and protect offspring. Its most important tool is its motor system, which consists of the voluntary and emotional motor systems. AIM: To explain how the brain uses its emotional motor system to control the pelvic organs. METHODS: Anatomic and physiologic data in cats and humans are used to find out how this motor system works and what parts of the brain and brainstem are involved...
October 2016: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/27872021/hypoactive-sexual-desire-disorder-a-review-of-epidemiology-biopsychology-diagnosis-and-treatment
#13
REVIEW
Sharon J Parish, Steven R Hahn
INTRODUCTION: Hypoactive Sexual Desire Disorder (HSDD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) as persistent deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), HSDD has been subsumed by Female Sexual Interest/Arousal Disorder. However, decades of research based on DSM-IV-TR HSDD criteria form the foundation of our understanding of the essential symptom of distressing low sexual desire, its epidemiology, clinical management, and treatment...
April 2016: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/27871953/prevalence-of-female-sexual-dysfunction-among-premenopausal-women-a-systematic-review-and-meta-analysis-of-observational-studies
#14
REVIEW
Megan E McCool, Andrea Zuelke, Melissa A Theurich, Helge Knuettel, Cristian Ricci, Christian Apfelbacher
INTRODUCTION: Epidemiologic research in female sexual dysfunction (FSD) has gained momentum in recent years, particularly in clinical populations and in menopausal women. However, sexual dysfunction also affects premenopausal women in general populations. Previous literature reviews have been unable to quantify the burden of FSD in general populations. This has been due in part to different definitions of dysfunction, heterogeneous study design, and the wide variety of measurement tools used...
July 2016: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/27858170/flibanserin-and-its-discontents
#15
REVIEW
Awais Aftab, Cheryl Chen, Jacob McBride
In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussion regarding the numerous controversies that have enclosed flibanserin since the very beginning. This includes questions related to flibanserin's safety and efficacy and the validity of the clinical trials. Also included are philosophical considerations surrounding the diagnosis of hypoactive sexual desire disorder and pharmacological treatment of low libido...
November 17, 2016: Archives of Women's Mental Health
https://www.readbyqxmd.com/read/27843072/toward-a-more-evidence-based-nosology-and-nomenclature-for-female-sexual-dysfunctions-part-ii
#16
Sharon J Parish, Andrew T Goldstein, Sue W Goldstein, Irwin Goldstein, James Pfaus, Anita H Clayton, Annamaria Giraldi, James A Simon, Stanley E Althof, Gloria Bachmann, Barry Komisaruk, Roy Levin, Susan Kellogg Spadt, Sheryl A Kingsberg, Michael A Perelman, Marcel D Waldinger, Beverly Whipple
INTRODUCTION: Current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) definitions of sexual dysfunction do not identify all sexual problems experienced clinically by women and are not necessarily applicable for biologic or biopsychosocial management of female sexual dysfunction. A unified nomenclature system enables clinicians, researchers, and regulatory agencies to use the same language and criteria for determining clinical end points, assessing research results, and managing patients...
December 2016: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/27823751/female-sexual-dysfunction-fsd-prevalence-and-impact-on-quality-of-life-qol
#17
REVIEW
Prof Rossella E Nappi, Laura Cucinella, Silvia Martella, Margherita Rossi, Lara Tiranini, Ellis Martini
Female sexual dysfunction (FSD) and quality of life (QOL) are both multidimensional and have a bidirectional relationship across the reproductive life span and beyond. Methodological difficulties exist in estimating the real prevalence of FSD because it is hard to determine the level of distress associated with sexual symptoms in a large-scale survey. Approximately 40-50% of all women report at least one sexual symptom, and some conditions associated with hormonal changes at menopause, such as vulvovaginal atrophy (VVA) and hypoactive sexual desire disorder (HSDD), have a significant impact on sexual function and QOL...
December 2016: Maturitas
https://www.readbyqxmd.com/read/27784209/systematic-review-and-meta-analysis-of-flibanserin-s-effects-and-adverse-events-in-women-with-hypoactive-sexual-desire-disorder
#18
Amirhossein Sahebkar, Seyed Hassan Saadat, Yunes Panahi, Ali Kabir, Khaled Rahmani, Milad Hosseinialhashemi
The efficacy and safety of flibanserin in the treatment of Hypoactive Sexual Desire Disorder (HSDD) is controversial. We reviewed existing evidence on the efficacy and safety of flibanserin in treating HSDD, and performed a meta-analysis of reported effects. Literature search was performed on PubMed, Scopus, and Cochrane library to find all trials on the efficacy of flibanserin in HSDD. Meta-analysis was performed using fixed- and random-effects models. Egger's test and "trim and fill" methods were used for the assessment of publication bias and imputation of potentially missing studies, respectively...
October 25, 2016: Current Drug Metabolism
https://www.readbyqxmd.com/read/27760089/efficacy-of-tribulus-terrestris-for-the-treatment-of-hypoactive-sexual-desire-disorder-in-postmenopausal-women-a-randomized-double-blinded-placebo-controlled-trial
#19
Karla Zanolla Dias de Souza, Fabiene Bernardes Castro Vale, Selmo Geber
OBJECTIVE: The objective of this study was to evaluate the efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women and evaluate its effect on the serum levels of testosterone. METHODS: We performed a prospective randomized, double-blinded, placebo-controlled study, during 18 months. A total of 45 healthy sexually active postmenopausal women reporting diminished libido were selected to participate in the study and were randomly assigned to receive 750 mg/d of T terrestris or placebo for 120 days...
November 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27738371/sexual-pain-among-malaysian-women-receiving-antidepressant-a-comparison-between-escitalopram-and-fluoxetine
#20
Hatta Sidi, Duni Asmidar, Loh Huai Seng, Nik Ruzyanei Nik Jaafar, Marhani Midi, Ng Chong Guan
OBJECTIVES: The current study compares the risk of sexual pain in depressed female patients in remission between those who were treated with Escitalopram and Fluoxetine. The associated factors were also examined. METHODS: This is a cross-sectional study involved 112 depressed female patients (56 treated with Escitalopram and 56 treated with Fluoxetine) who were in remission (as defined by Diagnostic and Statistical Manual-IV (DSM-IV) in the past 2 months and Montgomery-Asberg Depression Rating Scale (MADRS) score of ≤ 10) from the psychiatric clinic, University Kebangsaan Malaysia Medical Centre (UKMMC)...
March 1, 2016: Psychopharmacology Bulletin
keyword
keyword
113009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"